Pesquisar
ProQR Therapeutics NV
PRQRAdicionar à lista de desejos
1.810USD
+0.060+3.43%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
194.96MValor de mercado
PerdaP/L TTM
Mais detalhes de ProQR Therapeutics NV Empresa
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Informações de ProQR Therapeutics NV
Código da empresaPRQR
Nome da EmpresaProQR Therapeutics NV
Data de listagemSep 18, 2014
CEOde Boer (Daniel Anton)
Número de funcionários166
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 18
EndereçoZernikedreef 9
CidadeLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 CK
Telefone31881667000
Sitehttps://www.proqr.com/
Código da empresaPRQR
Data de listagemSep 18, 2014
CEOde Boer (Daniel Anton)
Executivos da empresa ProQR Therapeutics NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de ProQR Therapeutics NV?
Os cinco principais acionistas de ProQR Therapeutics NV são: Mr. Gerard Platenburg, Ph.D.
Quantas instituições possuem ações da ProQR Therapeutics NV (PRQR)?
Em 2026Q1, 122 instituições possuíam ações da ProQR Therapeutics NV, com valor de mercado aproximado de 38.34M, representando 36.39% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -5670621.00.